---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-003224"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:02:47.702272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances

## Summary
- Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.
- Cash and equivalents $137.7M at Dec 31, 2021; expects to fund operations through Q2 2023.
- Phase 3 Lumeos trial for XLRP enrolling; received $30M milestone from Janssen.
- Positive Phase 1 data for AAV-hAQP1 in xerostomia; Phase 2 start planned by end of 2022.
- R&D expenses $67.1M vs $33.9M, driven by ophthalmology, neurology, and manufacturing programs.

## SEC filing metadata
- accession: 0001558370-22-003224
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837022003224/0001558370-22-003224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837022003224/mgtx-20220310x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-003224
- JSON: https://secwatch.observer/filing/0001558370-22-003224.json
- Plain text: https://secwatch.observer/filing/0001558370-22-003224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.